This Is MS Multiple Sclerosis Knowledge & Support Community
Welcome to This is MS, the leading forum for Multiple Sclerosis research and support. Join our friendly community of patients, caregivers, and researchers celebrating over 20 years of delivering hope through knowledge. https://www.thisisms.com/forum/
...Michael Chopp, Ph.D., the scientific director for the Neuroscience Institute at Henry Ford Hospital. His research has focused on the cellular and molecular biology of cell injury; the microvascular pathophysiology of stroke, traumatic brain injury and neurodegenerative disease; laboratory models of stroke; and MRI.
Posted: Sat Jul 23, 2011 1:51 pm
by cheerleader
Great links, pair...great find, Cece. His specialty, as a neurological researcher, is addressing traumatic brain injury and stroke and the infiltration of white blood cells after injury . As we've learned on this board, and from Marie Rhode's excellent book www.ccsvibook.com the immune system reaction in the brain is not exclusive to MS.
Prof. Michael Chopp has continued his leadership of an outstanding research group at Henry Ford Hospital (HFH). An internationally recognized expert in the development and treatment of stroke, Prof. Chopp was one of a small international group of scientists invited by the World Health Organization to Geneva to discuss how best to study and treat this disease. He was also invited to give four plenary lectures on this topic at international conferences (as well as many other talks).
In support of his research, Prof. Chopp received four major grants from the National Institutes of Health (NIH) to HFH this year. Seven OU pre-doctoral students (W. Chen, K. Christopolou-Hurd, M. Jacobs, P. Jiang, S. Kaya, V. Nagesh, Z.G. Zhang) work in his laboratory. He plans to give an OU Physics Colloquium entitled "The Clot Thickens: Murder, Suicide, and MRI."
The focus of Prof. Chopp's research is the development of treatments for stroke. His goal is to salvage affected brain tissue. He and his group have recently identified novel death pathways of brain cells after stroke. After the onset of a stroke, brain cells undergo self destruction, a form of programmed cell death. This suicidal process is programmed by genetic alterations. They have identified proteins and genes resposible for the promotion of this form of cell death. With this knowledge, they may be able to intervene to inhibit this suicidal process of cell death.
They have also found that after a stroke secondary events contribute to the growth of the dead tissue. A major contributing factor to this secondary injury is the influx of white blood cells into the region of damage. They have identified the signalling molecules that target these cells to the site of injury and have blocked the function of these molecules. Their data indicate that using this therapeutic approach the amount of injured brain tissue is decreased by a factor of two, and that they can significantly reduce damage from stroke. Prof. Chopp and his group have also developed novel imaging methods using magnetic resonance imaging (MRI) that permit the non invasive evaluation of the health status of brain tissue. These techniques allow them to identify whether brain cells are simply affected and compromized by the stoke, are in the process of dying or are already dead. This imaging modality may have an important impact on the treatment of stroke patients and will likely improve the management of these patients.
http://www.oakland.edu/?id=10224&sid=249
No wonder he's interested in CCSVI...as a neurologist who studies ischemic brain injury, cellular death and the immune system reaction, he most certainly understands the connection--I hope he makes tons of pharma $
cheer
Posted: Sat Jul 23, 2011 2:01 pm
by Cece
I like him already.
He has a great background for this. It is also very good to be hearing from the neurological/neuroscience perspective.
He and his group have recently identified novel death pathways of brain cells after stroke. After the onset of a stroke, brain cells undergo self destruction, a form of programmed cell death. This suicidal process is programmed by genetic alterations. They have identified proteins and genes resposible for the promotion of this form of cell death.
So here is yet another way we might vary genetically, with some of us having a stronger or a weaker cell-suicide response to the low-grade ischemia of CCSVI.
INVITED SPEAKERS J. Steven Alexander, USA Bulent Arslan, USA
Raj Attariwala, CANADA Clive Beggs, UK
Ralph Benedict, USA
Randall Benson, USA
Michael Chopp, USA Chong P. Chung, TAIWAN
James R. Connor, USA John Cooke, USA Patricia Coyle, USA Michael Dake, USA
Diana Driscoll, CANADA Robert Fox, USA Yulin Ge, USA
Donato Gemmati, ITALY E. Mark Haacke, USA
Ziv J. Haskal, USA
Joseph Hewett, USA
Rick Hoge, CANADA Han-Hwa Hu, TAIWAN David Hubbard, USA
Csaba Juh Asz, USA
Nikolaos Liasis, GREECE
Michael Markl, USA Karen Marr, USA
Sandy McDonald, CANADA Erica Menegatti, ITALY
Sandra Morovic, ITALY-CROATIA
Andrew Nicolaides, ITALY Seshadri Raju, USA
Stefan Ropele, AUSTRIA Fabrizio Salvi, ITALY
Salvatore Sclafani, USA
Adnan Siddiqui, USA Marian Simka, POLAND
Kamil Ugurbil, USA
Gisel Viselner, ITALY Bianca Weinstock-Guttman, USA
Paolo Zamboni, ITALY
Robert Zivadinov, USA
I have bolded everyone I feel reasonably familiar with, but that leaves a lot of unbolded names. If you know anything interesting about the unbolded names, or the bolded ones, please share. It is not too early to get excited about ISNVD.
I notice Dr. Raju on the list. Dr. Raju and his fellow researcher, Dr. Neglen, are experts on May Thurner. I am excited to see him speaking at ISNVD. Way back in the early days, his technician posted here about doing CCSVI scans, and I have thought since then that he has experience to bring to CCSVI.
Karen Marr spoke at the American Access Care annual CCSVI symposium in July.
Dr. Fox is a neurologist but recently completed an autopsy study finding luminal abnormalities in MS patients. I am happy to see him participating in ISNVD. CCSVI is multi-disciplinary; we need our Dr. Fox's.
I think Dr. Hu and Dr. Chung from Taiwan are the doctors who have researched global transient amnesia and jugular valve insufficiency?
Re: Michael Chopp, keynote speaker, ISNVD 2012
Posted: Mon Oct 24, 2011 8:23 pm
by cheerleader
ISNVD will be very exciting this year! I can help bold a few of those names, Cece.
Dr. John Cooke is the doctor at Stanford who answered my e-mail about the endothelial health program, and months later put me in touch with Dr. Dake when I sent him the Zamboni research. His lab has been working on animal models (mouse and marmoset) of CCSVI.
Dr. J. Steven Alexander is from LSU. Met him in Bologna, he had read Marie and my writing on here, knew me as "cheer." He is an endothelial researcher, and is publishing on cerebral endothelial disruption in CCSVI.
Dr. Patricia Coyle is a neurologist from Stony Brook. I met her at the first Bologna conference. She's CCSVI curious, but has not participated in any research or publications on it.
Dr. Yulin Ge is from NYU and has done much research on SWI technology in MS. He and Dr. Haacke have worked together on understanding the vasculature and iron deposition in MS.
-you're right about Dr. Chung. He's the Taiwanese researcher who has been looking at IJVVI and TGA for a decade.
I think Dr. Hu and Dr. Chung from Taiwan are the doctors who have researched global transient amnesia and jugular valve insufficiency?
Those are the Doctors who found my LIJV is >90% blocked. They operated 8 patients with results ranging from slight improvements to remarkable recovery. As it is still experimental and that my EDSS is pretty high; they want to wait for expanding the procedure.
Re: Michael Chopp, keynote speaker, ISNVD 2012
Posted: Tue Oct 25, 2011 9:02 am
by Cece
Algis wrote:Those are the Doctors who found my LIJV is >90% blocked. They operated 8 patients with results ranging from slight improvements to remarkable recovery. As it is still experimental and that my EDSS is pretty high; they want to wait for expanding the procedure.
Maybe participating in ISNVD will move them towards the time when they are confident in doing your procedure, Algis. With my left jugular, also with a near total blockage, there was some comfort in knowing that it couldn't get worse.
Ok, Dr. Cooke's name is very familiar, I should have known him.
Here's more on Dr. Alexander. Not an IR or a vascular surgeon or a physicist or a neurologist but a cardiovascular biologist! Yet another discipline for our multidisciplinary endeavor.
Dr. Alexander is an cardiovascular biologist working on how small blood vessels become injured during the process of inflammation. Several diseases including stroke, cancer, Crohn's disease and diabetes are associated with disturbances in how blood vessels restrict exchange of their contents, leading to the development of edema. Our current models indicate the dysregulation of several classes of junctional molecules (tight or occludens junctions, adherens junctions and complexus adherents junctions) mediate the elevated exchange of solute proteins and inflammatory cells during active inflammation. A new and important direction in this area of research is the development of models which consider the lymphatic system and the growth of lymphatic endothelial cells which is known to participate in tumor cell metastasis, but also acute and chronic inflammation.
SCIENTIFIC MEETING - OVERVIEW
Saturday, February 18, 2012
1:00PM 3:00PM Consensus Workshop on Vascular Imaging in CCSVI: Ultrasound Session
3:30PM 5:30PM Consensus Workshop on Vascular Imaging in CCSVI: MR Imaging Session
Sunday, February 19, 2012
8:30AM 10:00AM Consensus Breakout Session
10:30AM 12:00PM Multi-Modal Imaging in CCSVI (Integrating Multi-Modal Imaging Standard)
1:00PM 2:00PM Official Opening of the 2nd Annual Scientific Meeting
2:30PM 3:30PM Abnormal Venous Flow and Neurodegenerative Disease: Part 1
3:30PM 4:30PM Abnormal Vasculature in Neurological Disease Panel Discussion
7:00PM 9:00PM Evening Reception
Monday, February 20, 2012
8:30AM 10:00AM Perfusion, Hypoxia, Ischemia, Reperfusion
10:30AM 12:00PM Abnormal Venous Flow and Neurodegenerative Disease: Part 2
1:00PM 2:30PM CCSVI Introduction: Part 1
3:00PM 4:30PM CCSVI Consensus Guidelines for Diagnosis: Part 2
4:30PM 5:30PM Abnormal Vasculature in Neurological Disease Panel Discussion
Tuesday, February 21, 2012
8:30AM 10:00AM Abnormal Venous Flow and Neurodegenerative Disease: Part 3
10:30AM 12:00PM Iron and its Role In Neurovascular Diseases
1:00PM 2:30PM CCSVI Computational Fluid Dynamics and Measuring Flow: Part 3
3:00PM 4:00PM Abnormal Vasculature in Neurodegenerative Disease: Part 4 - Optical Issues
4:00PM 5:30PM Abstract Presentations
Wednesday, February 22, 2012
8:30AM 10:00AM CCSVI Clinical Trials Methodological Considerations: Part 4
10:30AM 12:00PM Treatment: Abnormal Venous Vasculature in Other diseases
1:00PM 3:00PM Abstract Presentations and Abstract Awards
3:30PM 5:00PM CCSVI Clinical Trials Outcomes: Part 5
5:00PM 5:30PM Closing Session: Passing of the Gavel
Re: Michael Chopp, keynote speaker, ISNVD 2012
Posted: Mon Nov 28, 2011 11:34 am
by Cece
That's just the overview. It gets much more detailed.
Treatment of other venous diseases: Abnormal venous vasculature in other diseases
(10:30am – 12:00pm) Clinical manifestations of acute and chronic venous obstruction in superior vena cava syndrome
(Ziv J. Haskal, USA)
Lessons from endovascular management of lower extremity venous obstruction (Seshadri Raju, USA)
Consequences of venous obstruction involving other vascular beds (Salvatore Sclafani, USA)
Idiopathic intracranial hypertension: similarities & differences with CCSVI (Randall Benson, USA)
Occlusion, recanalization and thrombolysis (Bulent Arslan, USA)
Here we have Dr. Haskal, talking about superior vena cava syndrome, which is a disease to which Dr. Dake has compared CCSVI.
Then there is Dr. Raju, of Mississippi, who is an acknowledged expert on May-Thurner syndrome. I've been waiting for more from him since January 2010, when his technician posted here at TiMS! ( http://www.thisisms.com/forum/chronic-c ... ml#p117563 for copied text.)
Then there is our hometown favorite, Dr. Sclafani, talking about the consequences of venous obstruction involving other vascular beds. I am taking this to be obstuction of the renal vein as in Nutcracker syndrome.
Dr. Benson is a neurologist from Wayne State University, which is where Dr. Haacke works as well. I am more aware of the similarities between idiopathic intracranial hypertension and CCSVI than the differences.
Dr. Arslan is an IR in Florida. There was a great interview with him: http://www.thisisms.com/forum/chronic-c ... fe#p170969 At ISNVD he is talking about occlusion, recanalization and thrombolysis. We have certainly seen occlusions in CCSVI, unfortunately. Do we have less likelihood of natural recanalization in CCSVI? Perhaps the postural flow dependence of jugulars and the presence of collaterals makes them more likely to stay clotted if they do clot. Thrombolysis seems to be not much used in CCSVI when clotting occurs, in favor of other techniques such as manual clot removal or doing nothing (!) or rendez-vous procedures. The death of the patient in Costa Rica was after being treated with thrombolysis.
Re: Michael Chopp, keynote speaker, ISNVD 2012
Posted: Mon Nov 28, 2011 11:42 am
by Cece
Abstract Presentations and Abstract Awards (1:00pm – 3:00pm)
James F. McGuckin (USA) and Matteo Coen (Switzerland) and others to be chosen from selected abstracts
Dr. McGuckin has an abstract in! I wonder what his findings were.
We have examined several venous specimens from MS patients in which CCSVI had
been diagnosed. Five of these specimens were obtained from patients undergoing
jugular vein reconstruction after restenosis following angioplasty and 10 additional
specimens were obtained from a patient with MS and CCSVI who died for unrelated
causes. Five control specimens were obtained at autopsy of patients who died for non
neurological diseases.
This was looking at actual specimens of ccsvi stenoses. There appears to be a change in collagen, in the "extracellular matrix," with a switch from collagen I to collagen III. Would love it if there has been further research on this.
Re: Michael Chopp, keynote speaker, ISNVD 2012
Posted: Mon Nov 28, 2011 11:45 am
by Cece
Closing Session: Passing of the Gavel (5:00pm – 5:30pm)
Robert Zivadinov, President 2011-2012
Marian Simka, President 2012-2013
Congrats and appreciation to Dr. Simka, our next ISNVD president! And equal appreciation to Dr. Zivadinov, for what he has done this year.
